Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Muhamed BaljevicCristina GasparettoGary J SchillerSascha A TuchmanNatalie S CallanderSuzanne LentzschJorge MongeRami KotbNizar J BahlisDarrell WhiteChristine I ChenHeather J SutherlandSumit MadanRichard LeBlancMichael SebagChristopher P VennerWilliam I BensingerNoa BiranAndrew DeCastroDane R Van DomelenChris ZhangJatin J ShahSharon ShachamMichael G KauffmanOhad S BenturBrea LipePublished in: EJHaem (2022)
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients' prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.
Keyphrases
- cell therapy
- multiple myeloma
- emergency department
- end stage renal disease
- stem cells
- newly diagnosed
- electronic health record
- ejection fraction
- mesenchymal stem cells
- combination therapy
- machine learning
- replacement therapy
- cancer therapy
- drug delivery
- single cell
- prognostic factors
- peritoneal dialysis
- clinical practice
- patient reported outcomes